Q1 2025 Stryker Corp Earnings Call Transcript
Key Points
- Stryker Corp (SYK) reported robust organic sales growth of 10.1% in Q1 2025, with strong performances in MedSurg, neurotechnology, and orthopedics.
- The company achieved double-digit organic growth in the US across several business segments, including trauma and extremities, neurocranial, medical, endoscopy, and instruments.
- International markets showed healthy growth, particularly in Australia, New Zealand, Japan, and Europe, indicating significant future growth potential.
- Stryker Corp (SYK) completed the acquisition of Inari Medical, which is integrating well and expected to contribute positively to the vascular division.
- The company raised its full-year organic sales growth guidance to 8.5% to 9.5% and expects adjusted EPS of $13.20 to $13.45, reflecting strong commercial execution and innovation pipelines.
- Stryker Corp (SYK) faces a $200 million impact from tariffs in 2025, which they are working to mitigate through sales momentum and cost management.
- The company experienced supply chain disruptions affecting its medical business, which are expected to continue through Q2.
- Foreign currency had a 0.9% unfavorable impact on sales, affecting overall financial performance.
- The US Spinal Implant business was flat organically, and the US other ortho business declined 1.9% organically due to changes in Mako deal mix and a decline in bone cement.
- Higher SG&A spending, driven by the Inari acquisition and other growth investments, partially offset the gross margin favorability.
Welcome to the first quarter 2025 Stryker earnings call. My name is Luke, and I'll be your operator for today's call. (Operator Instructions) This conference call is being recorded for replay purposes. Before we begin, I'd like to remind you that the discussions during this conference call will include forward-looking statements.
Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that's an exhibit to Stryker 's current report on Form 8-K filed today with the SEC.
I'd now like to turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.
Welcome to Stryker's first quarter earnings call. Joining me today are Preston Wells, Stryker's CFO; and Jason Beach, Vice President of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
